Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
暂无分享,去创建一个
C. Paweletz | R. Bueno | R. Salgia | J. Griffin | K. Podar | M. Sattler | D. Frank | P. Gokhale | M. Lapidot | E. Weisberg | Chengcheng Meng | Abigail E Case | Michael J. Poitras | D. Larios | S. Saladi | C. Meng | I. Tošić | Helen Gandler
[1] J. Aerts,et al. Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? , 2020, Frontiers in Oncology.
[2] Prakash Kulkarni,et al. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma , 2019, Oncogenesis.
[3] David L. Gibbs,et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. , 2018, Cancer discovery.
[4] M. Berry,et al. Diagnosis and management of mesothelioma , 2018, AME Medical Journal.
[5] G. Santoni,et al. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy. , 2018, Current protein & peptide science.
[6] Roger D Kamm,et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. , 2018, Lab on a chip.
[7] F. Greten,et al. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. , 2018, Cancer cell.
[8] B. Vojtesek,et al. STAT3, stem cells, cancer stem cells and p63 , 2018, Cellular & Molecular Biology Letters.
[9] T. Baumert,et al. Viral manipulation of STAT3: Evade, exploit, and injure , 2018, PLoS pathogens.
[10] D. Frank,et al. Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. , 2017, Trends in cancer.
[11] K. Schalper,et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. , 2017, Cancer treatment reviews.
[12] L. Kenner,et al. JAK-STAT signaling in cancer: From cytokines to non-coding genome. , 2016, Cytokine.
[13] Traci M. Blonquist,et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. , 2016, Blood.
[14] Jesus Hernandez-Monge,et al. Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB , 2016, Genes & cancer.
[15] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[16] H. Pass,et al. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations , 2015, Oncotarget.
[17] J. Coward,et al. The role of interleukin-6 in malignant mesothelioma. , 2015, Translational lung cancer research.
[18] B. Groner,et al. Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival , 2014, Clinical Cancer Research.
[19] M. Shingyoji,et al. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. , 2013, American journal of clinical pathology.
[20] P. Sharma,et al. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. , 2011, Cancer research.
[21] A. Takakura,et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. , 2011, Human molecular genetics.
[22] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[23] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[24] G. Gordon,et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. , 2009, Journal of the National Cancer Institute.
[25] D. Chauhan,et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. , 2008, Blood.
[26] P. Cagle,et al. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. , 2007, Archives of pathology & laboratory medicine.
[27] S. Eschrich,et al. Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.
[28] J. Prieto,et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 , 2005, International journal of cancer.
[29] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Baggish,et al. Antiparasitic Agent Atovaquone , 2002, Antimicrobial Agents and Chemotherapy.
[31] J. Turkson,et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.
[32] G. Viale,et al. Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.
[33] B. Luft,et al. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii , 1996, Antimicrobial agents and chemotherapy.
[34] K. Matsushima,et al. Essential involvement of interleukin‐8 (IL‐8) in acute inflammation , 1994, Journal of leukocyte biology.
[35] Zhi Wei,et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.
[36] Zachary T. Giaccone,et al. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer , 2017, Cancer Immunology, Immunotherapy.
[37] M. Ward,et al. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. , 1999, Oncology research.
[38] P. Vogt,et al. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.